Synthetic Biologics is a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients. Our lead candidates poised for Phase 3 development are: (1) SYN-004 (ribaxamase) which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) beta-lactam antibiotics for the prevention of C. difficile infection (CDI), pathogenic overgrowth and the emergence of antimicrobial resistance (AMR), and (2) SYN-010 which is intended to reduce the impact of methane producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C). We are also developing preclinical stage monoclonal antibody therapies for the prevention and treatment of pertussis and novel discovery stage biotherapeutics for the treatment of phenylketonuria (PKU).
42nd World Hospital Congress presented by The Australian Healthcare and Hospitals Association (AHHA) and International Hospital Federation (IHF)
10-12 October 2018 | Brisbane Convention & Exhibition Centre (BCEC), Merivale St & Glenelg Street, South Brisbane QLD 4101
www.hospitalcongress2018.com | Event hashtag: #IHFBrisbane2018
Iceberg Events | PO Box 1179, Milton Qld Australia | Phone +61 7 3876 4988